Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum

Journal of Clinical Investigation

Volumn 101, Issue 2, 1998, Pages 344-352

  Kornmann, Marko ^a   Arber, Nadir ^b   Korc, Murray ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cell cycle; Chemosensitivity; Growth factor; Kinase activity; Nude mice

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; CYCLIN D1; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGENIC AGENT; SOMATOMEDIN C;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENICITY; CELL CYCLE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL;

EID: 0032518616     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI1323     Document Type: Article

References (52)

1. Pines, J. 1994. Protein kinases and cell cycle control. Semin. Cell Biol. 5: 399-408.
2. Grana, X., and E.P. Reddy, 1995. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 11:211-219.
3. Draetta, G.F. 1994. Mammalian G1 cyclins. Curr. Opin. Cell Biol. 6:842-846.
4. Sherr, C.J. 1994. G1 phase progression: cyclin on cue. Cell. 79:551-555.
5. 1 events and regulation of cell proliferation. Science. 246:603-608.
6. Buchkovich, K., L.A. Duffy, and E. Harlow. 1989. The retinoblastoma protein is phosphorylated during special phases of the cell cycle. Cell. 58:1097-1105.
7. Dowdy, S.F., P.W. Hinds, K. Louie, S.I. Reed, A. Arnold, and R.A. Weinberg. 1993. Physical interaction of the retinoblastoma protein with human D cyclins. Cell. 73:499-511.
8. Even, M.E., H.K. Sluss, C.J. Sherr, H. Matsushime, J.-Y. Kato, and D.M. Livingston. 1993. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell. 73:487-497.
9. Lam, E.W.-F., and N.B. La Thangue. 1994. DP and E2F proteins: coordinating transcription with cell cycle progression. Curr. Opin. Cell Biol. 6:859-866.
10. Wu, C.-L., L.R. Zukerberg, C. Ngwu, E. Harlow, and J.A. Lees. 1995. In vivo association of E2F and DP family proteins. Mol. Cell. Biol. 15:2536-2546.
11. Jiang, W., S.M. Kahn, P. Zhou, Y.-J. Zhang, A.M. Cacace, A.S. Infante, S. Doi, R.M. Santella, and I.B. Weinstein. 1993. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene. 8:3447-3457.
12. Quelle, D.E., R.A. Ashmun, S.A. Shurtleff, J.-Y. Kato, D. Bar-Sagi, M.F. Roussel, and C.J. Sherr. 1993. Overexpression of mouse D type cyclins accelerates G1 phase in rodent fibroblasts. Genes Der. 7:1559-1571.
13. Resnitzky, D., M. Gossen, H. Bujard, and S.I. Reed. 1994. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol. Cell. Biol. 14:1669-1679.
14. Motokura, T., and A. Arnold. 1993. Cyclins and oncogenesis. Biochim. Biophys. Acta. 1155:63-78.
15. Parker, S.L., T. Tong, S. Bolden, and P.A. Wingo. 1996. Cancer Statistics, 1996. CA Cancer J. Clin. 65:5-27.
16. Korc, M., B. Chandrasekar, Y. Yamanaka, H. Friess, M. Büchler, and H.G. Beger. 1992. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concumitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J. Clin. Invest. 90:1352-1360.
17. Kobrin, M.S., Y. Yamanaka, H. Friess, M.E. Lopez, and M. Korc. 1993. Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res. 53:4741-4744.
18. Yamanaka, Y., H. Friess, M. Büchler, H.G. Beger, E. Uchida, M. Onda, M.S. Kobrin, and M. Korc. 1993. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res. 53:5289-5296.
19. Bergmann, U., H. Funatomi, M. Yokoyama, H.G. Beger, and M. Korc. 1995. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res. 55:2007-2011.
20. Link, K.H., F. Gansauge, J. Pillasch, and H.G. Beger. 1997. Multimodal therapies in ductal pancreatic cancer. The future. Int. J. Pancreatol. 21:71-83.
21. Gansauge, S., F. Gansauge, M. Ramadani, H. Stobbe, B. Rau, N. Harada, and H.G. Beger. 1997. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res. 57:1634-1637.
22. Kornmann, M., T. Ishiwata, J. Itakura, P. Tangvoranuntakul, H.G. Beger, and M. Korc. 1998. Oncology. In press.
23. Zhou, P., W. Jiang, Y.-J. Zhang, S.M. Kahn, I. Schieren, R.M. Santella, and B. Weinstein. 1995. Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene. 11:571-580.
24. Moriai, T., M.S. Kobrin, C. Hope, L. Speck, and M. Korc. 1994. A variant epidermal growth factor receptor exhibits altered type a transforming growth factor binding and transmembrane signaling. Proc. Natl. Acad. Sci. USA. 91:10217-10221.
25. Arber, N., Y. Doki, E.K.-H. Han, A. Sgambato, P. Zhou, N.-H. Kim, T. Delohery, M.G. Klein, P.R. Holt, and I.B. Weinstein. 1997. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res. 57:1569-1574.
26. Lukas, J., J. Bartkova, and J. Bartek. 1996. Convergence of mitogenic signaling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol. Cell. Biol. 16:6917-6925.
27. Matsushime, H., D.E. Quelle, S.A. Shurtleff, M. Shibuya, C.J. Sherr, and J.-Y. Kato, 1994. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol. 14:2066-2076.
28. Mossmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:55-63.
29. Kornmann, M., T. Ishiwata, H.G. Beger, and M. Korc. 1997. Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine events. Oncogene. 15: 1417-1424.
30. Raitano, A.B., and M. Korc. 1990. Tumor necrosis factor up-regulates γ-interferon binding in a human carcinoma cell line. J. Biol. Chem. 265:10466-10472.
31. Baldwin, R.L., and M. Korc. 1993. Growth inhibition of human pancreatic carcinoma cells by transforming growth factor beta-1. Growth Factors. 8: 23-34.
32. Link, K.H., G. Leder, J. Pillasch, U. Butzer, L. Staib, M. Kornmann, U.B. Brückner, and H.G. Beger. 1998. In vitro concentration response studies and in vitro phase II tests as the experimental base of regional chemotherapeutic protocols. Semin. Surg. Oncol. In press.
33. Hamburger, A.W., and S.E. Salmon. 1977. Primary bioassay of human tumor stem cells. Science. 197:461-463.
34. Hall, M., and G. Peters. 1996. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 68:67-108.
35. Baldin, V., J. Lukas, M.J. Marcote, M. Pagano, and G. Draetta. 1993. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7:812-821.
36. Schrump, D.S., A. Chen, and U. Consoli. 1996. Inhibition of lung cancer proliferation by antisense cyclin D. Cancer Gene Ther. 3:131-135.
37. Naitoh, H., J. Shibata, A. Kawaguchi, M. Kodama, and T. Hattori. 1995. Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am. J. Pathol. 146:1161-1169.
38. McIntosh, G.G., J.J. Anderson, I. Milton, M. Steward, A.H. Parr, M.D. Thomas, J.A. Henry, B. Angus, T.W.J. Lennard, and C.H.W. Horne. 1995. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene. 11:885-891.
39. Caldas, C., S.A. Hahn, L.T. da Costa, M.S. Redston, M. Schutte, A.B. Seymour, C.L. Weinstein, R.H. Hruban, C.J. Yeo, and S.E. Kern. 1994. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 8:27-32.
40. Huang, L., T.L. Goodrow, S.-Y. Zhang, A.J.P. Klein-Szanto, H. Chang, and B.A. Ruggeri. 1996. Deletion and mutation analyses of the p16/mts-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res. 56:1137-1141.
41. Naumann, M., N. Savitskaia, C. Eilert, A. Schramm, H. Kalthoff, and W. Schmiegel. 1996. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology. 110: 1215-1224.
42. Weiss, B., G. Davidkova, and S.-P. Zhang. 1997. Antisense strategies in neurobiology. Neurochem. Int. 31:321-348.
43. Kawasaki, H., M. Machida, M. Komatsu, H.-O. Li, T. Murata, H. Tsutsui, A. Fujita, M. Matsumura, Y. Kobayashi, K. Taira, and K.K. Yokoyama. 1996. Specific regulation of gene expression by antisense nucleic acids: a summary of methodologies and associated problems. Artificial Organs. 20:836-848.
44. Korc, M., P. Meltzer, and J. Trent. 1986. Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc. Natl. Acad. Sci. USA. 83:5141-5144.
45. Smith, J.J., R. Derynck, and M. Korc. 1987. Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc. Natl. Acad. Sci. USA. 84:7567-7570.
46. Yokoyama, M., H. Funatomi, C. Hope, D. Damm, H. Friess, M.W. Büchler, J. Abraham, and M. Korc. 1996. Heparin-binding EGF-like growth factor expression and biological action in human pancreatic cancer cells. Int. J. Oncol. 8:289-295.
47. Berrrozpe, G., J. Schaeffer, M.A. Peinado, F.X. Real, and M. Perucho. 1994. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int. J. Cancer. 58:185-191.
48. Liu, Q., Y.-X. Yan, M. McClure, H. Nakagawa, F. Fujimura, and A.K. Rustgi. 1994. MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. Oncogene. 12:619-622.
49. Rozenblum, E., M. Schutte, M. Goggins, S.A. Hahn, S. Panzer, M. Zahurak, S.N. Goodman, T.A. Sohn, R.H. Hruban, C.J. Yeo, and S.E. Kern. 1997. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 57: 1731-1734.
50. Hochhauser, D., B. Schnieders, E. Ercikan-Abali, R. Gorlick, R. Muise-Helmericks, W.-W. Li, J. Fan, D. Banerjee, and J.R. Bertino. 1996. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. J. Natl. Cancer Inst. 88:1269-1275.
51. Black, D.J. and R.B. Livingston. 1990. Antineoplastic drugs in 1990. A review (Part II). Drugs. 39:652-673.
52. Wagner, M., T. Cao, M.E. Lopez, C. Hope, K. Van Nordstrand, M.S. Kobrin, H.U. Fan, M.W. Büchler, and M. Korc. 1996. Expression of a truncated EGF receptor is associated with inhibition of pancreatic cancer cell growth and enhanced sensitivity to cisplatinum. Int. J. Cancer. 68:782-787.